The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.a

Pneumonitis (interstitial lung disease/ILD)

Publications

Gao X, He D, Yang H, Pang X, Liang L

Almonertinib-Induced Interstitial Lung Disease in an NSCLC Patient Harboring an EGFR Ex19del Mutation: A Case Report.

Case reports in oncology 2026;19 — 2026 — 490-498

Zhou Q, Hu Z, Li X, Tang X

Almonertinib-induced interstitial lung disease in a lung adenocarcinoma patient complicated with interstitial lung abnormality.

BMC pulmonary medicine 2023 Mar 08;23 — 2023 Mar 08 — 79

Jiang T, Luo Y, Wang B

Almonertinib-induced interstitial lung disease: A case report.

Medicine 2021 Jan 22;100;e24393 — 2021 Jan 22 — e24393